Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 4/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL848969 | 0.87 | FOLH1 (0.56) | ANPEPENPEPFOLH1MEP1BMRGPRX4 | |
| SCHEMBL22690106 | 0.85 | ANPEP (0.56) | ANPEPENPEPFOLH1 | |
| SCHEMBL14478232 | 0.85 | ANPEP (0.69) | ANPEPENPEPFOLH1 | |
| SCHEMBL1397444 | 0.85 | ANPEP (0.69) | ANPEPENPEPFOLH1 | |
| SCHEMBL9622159 | 0.85 | ANPEP (0.69) | ANPEPENPEPFOLH1 | |
| SCHEMBL25355588 | 0.84 | ANPEP (0.55) | ANPEPENPEPFOLH1 | |
| SCHEMBL25355590 | 0.84 | ANPEP (0.55) | ANPEPENPEPFOLH1 | |
| Hydrochloric Acid SCHEMBL27656347 | 0.83 | ANPEP (0.67) | ANPEPENPEPFOLH1 | |
| SCHEMBL10651279 | 0.83 | SLC7A5 (0.62) | MRGPRX4SMN1; SMN2 | |
| SCHEMBL23546238 | 0.81 | GRIN2D (0.68) | ANPEPENPEPFOLH1MEP1BMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | claimed |
| US-20230331685-A1 | HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF | AG PLENUS LTD (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20230331685-A1 | HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF | AG PLENUS LTD (IL) | 2023-10-19 | — | — | US | disclosed |
| WO-2023081893-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-20170157198-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-06-08 | — | — | US | disclosed |
| EP-3052121-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | CDK4, CDK2, CDK8 | ANPEP 1064/4885ENPEP 808/4885FOLH1 3060/4885 |
| US-20230331685-A1 | HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF | DDT, HDHD5, HPD | ANPEP 568/4885ENPEP 670/4885FOLH1 1306/4885 |
| US-20170157198-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | ANPEP 107/4885ENPEP 298/4885FOLH1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.